Background
==========

Ischemic and hemorrhagic stroke are major causes of morbidity and mortality worldwide \[[@B1]\]. During recent years it has become clear that systemic inflammation may enhance atherogenesis \[[@B2]-[@B4]\]. Immune-mediated diseases (IMDs) are a heterogenous group of diseases that are characterized by acute or chronic inflammation \[[@B2]-[@B8]\]. Some IMDs have been associated with an increased risk for cardiovascular disease \[[@B2]-[@B8]\]. IMDs may increase the cardiovascular disease risk through different mechanisms such as autoreactive lymphocytes, autoantibodies, autoantigens, epigenetic mechanisms, and inflammation driving the formation, progression and rupture of atherosclerotic plaques \[[@B2]-[@B8]\]. Inflammation may also affect the thrombotic risk by suppressing fibrinolysis, upregulating procoagulants, and downregulating anticoagulants \[[@B7]\]. Thus, certain IMDs such as rheumatoid arthritis (RA) \[[@B3],[@B5],[@B6],[@B8]-[@B12]\] and systemic lupus erythematosus (SLE) \[[@B3],[@B5],[@B6],[@B8],[@B13]-[@B15]\] have been associated with an increased risk of cardiovascular disease. Enhanced atherogenesis has also been indicated in other IMDs such as Sjögren´s disease \[[@B3],[@B5],[@B6],[@B16]\], systemic vasculitis \[[@B3],[@B5]\], inflammatory bowel disease \[[@B3],[@B5],[@B8],[@B17]\], and psoriasis \[[@B8],[@B18]\]. As a consequence of this, the risk of stroke has been reported to be increased in patients with systemic lupus erythematosus \[[@B19]\] and rheumatoid arthritis \[[@B20]\].

We hypothesized that not only IMDs such as SLE and RA, but also a number of other less well-studied IMDs have an increased risk of cardiovascular disease. More specifically, we aimed at determining whether IMDs increase the risk for hospitalized ischemic or hemorrhagic stroke. In a nationwide follow-up from 1987--2008 we have estimated the risk of hospitalization with stroke in patients hospitalized with 32 different IMDs without previous or coexisting stroke.

Methods
=======

This study was approved by the Ethics Committee of Lund University, Sweden. Data used in this study contained information on all individuals registered as residents of Sweden \[[@B21]\]. It included individual-level information on age, sex, occupation, geographic region of residence, hospital diagnoses, and dates of hospital admissions in Sweden (1964--2008), as well as date of emigration, and date and cause of death \[[@B21]\]. The dataset was constructed using several national Swedish data registers (reviewed by Rosen and Hakulinen) \[[@B22]\], including, but not limited to, the Swedish National Population and Housing Census (1960--1990), the Total Population Register, the Multi-Generation Register, and the Swedish Hospital Discharge Register \[[@B23]\]. The data were released to us from the National Board of Health and Welfare and Statistics Sweden.

Information retrieved from the various registers was linked, at the individual level, via the national 10-digit personal identification number assigned to each resident of Sweden for his or her lifetime. Registration numbers were replaced by serial numbers to preserve anonymity. As well as being used to track all records in the database at the individual level, these serial numbers were used to check that individuals with hospital diagnoses of ischemic or hemorrhagic stroke appeared only once during the follow-up (for the first hospital diagnosis of ischemic or hemorrhagic stroke during the study period).

The follow-up period for analysis of data in the present study started on January 1, 1987 and continued until hospitalization for ischemic or hemorrhagic stroke, death, emigration, or the end of the study period (December 31, 2008). Data for first hospitalization for ischemic or hemorrhagic stroke during the study period were retrieved from the Hospital Discharge Register (1987--2008). This study did not include data for hospital outpatients or patients treated at primary health care centers.

Predictor variable
------------------

The predictor variable was hospitalization for an IMD, diagnosed according to ICD-7, ICD-8, ICD-9, and ICD-10 (Additional file [1](#S1){ref-type="supplementary-material"} Table S1).

Outcome variable
----------------

Diagnosis of ischemic stroke was based on the 9th, and 10th revisions of the International Classification of Diseases (ICD-9, and ICD-10). Cases of ischemic stroke were identified using the following ICD codes: 433, 434, 435, 437.0, and 437.1 (ICD-9); and I63 (not I636), I65, I66, I67.2, and I67.8 (ICD-10).

Diagnosis of hemorrhagic stroke was also based on ICD-9, and ICD-10. Cases of hemorrhagic stroke were identified using the following ICD codes: 431 and 432 (ICD-9); and I61 and I62 (ICD-10).

Individual-level variables adjusted for in the model
----------------------------------------------------

The individual-level variables were sex, age, time period, geographic region of residence, socioeconomic status (SES), and comorbidity.

Sex: male or female.

Age was divided into 5-year categories. Subjects of all ages were included in the study.

Time period was divided into five time periods in order to allow for adjustment for any change in hospitalization rates over time: 1987--1991, 1992--1996, 1997--2001, 2002--2008.

Geographic region of residence was included as an individual-level variable to adjust for possible differences in hospital admissions for ischemic or hemorrhagic stroke between different geographic regions in Sweden. It was categorized as: 1) large city (city with a population of \>200,000 (i.e., Stockholm, Gothenburg, or Malmo); 2) Southern Sweden (both rural and urban); and 3) Northern Sweden (both rural and urban).

Occupation was used as a proxy for SES. We classified each individual's occupation into one of six categories: 1) blue-collar worker, 2) white-collar worker, 3) professional, 4) self-employed, 5) farmer, and 6) non-employed (Individuals without paid employment). Homemakers and students without an occupation were categorized on the basis of their husband's, father's or mother's occupation. If that was not possible, they were included in the "non-employed" category. For individuals aged \<20 years, parental occupation was used.

Comorbidity was defined as the first hospital diagnosis at follow up (1987--2008) of the following: 1) chronic lower respiratory diseases (490--496 (ICD-9), and J40--J49 (ICD-10)); 2) obesity (278A (ICD-9), and E65--E68 (ICD-10)); 3) alcoholism and alcohol-related liver disease (291 and 303 (ICD-9), and F10 and K70 (ICD-10)); 4) type 2 diabetes mellitus (250 (age \>29 years) (ICD-9), and E11-E14 (ICD-10)); 5) hypertension (401--405 (ICD-9), and I10--I15 (ICD-10)); 6) atrial fibrillation (427D (ICD-9), and I48 (ICD-10)); 7) heart failure (428 (ICD-9), and I50 (ICD-10)); 8) renal disease (580--591 and 753B (ICD-9), and N00-N19, Q61 (ICD-10)); 9) sepsis (036,038 (ICD-9), and A39-A41 (ICD-10)); and 10) coronary heart disease (410--414 (ICD-9), and I20-I25 (ICD-10)).

Statistical analysis
--------------------

Person-years at risk (i.e., number of persons at risk multiplied by time at risk) were calculated from the time at which subjects were included in the study (in 1987 or later) until first hospitalization for ischemic or hemorrhagic stroke, death, emigration, or the end of the study period. Person years for IMD patients were calculated from discharge of first hospitalization for IMD (IMD patients with previous stroke before the first IMD hospitalization or at the same hospitalization as the first IMD hospitalization, were excluded). The expected number of cases was based on the number of cases in the reference group. SIRs were calculated as the ratio of observed (O) and expected (E) number of ischemic or hemorrhagic stroke cases using the indirect standardization method \[[@B24]\]:

$$SIR = \frac{\sum_{j - 1}^{J}o_{j}}{\sum_{j - 1}^{J}n_{j}\lambda_{j}^{*}} = \frac{o}{E^{*}}\text{,}$$

Where $o = \sum o_{j}$ denotes the total observed number of cases in the study group; $E^{*}$ (expected number of cases) is calculated by applying stratum-specific standard incidence rates $\left( \lambda_{j}^{*} \right)$ obtained from the reference group to the stratum-specific person-years (*n*) of risk for the study group; ${{}^{o}}_{j}$ represents the observed number of cases that the cohort subjects contribute to the jth stratum; and J represents the strata defined by cross-classification of the following adjustment variables: age, sex, time period, SES, geographic region of residence, and comorbidity \[[@B24]\]. Ninety-five percent confidence intervals (95% CIs) were calculated assuming a Poisson distribution \[[@B24]\]. All analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC, USA).

Results
=======

Table [1](#T1){ref-type="table"} shows the number of people admitted to hospital with each of the selected IMDs during the study period. IMD patients with previous stroke before first hospitalization for IMD or stroke at the same time as first IMD hospitalization were excluded from Table [1](#T1){ref-type="table"}. Totally 8113 IMD patient with previous or coexisting ischemic stroke and 1416 with hemorrhagic stroke were excluded. A total of 216,291 individuals were hospitalized with an IMD (82,258 males and 134,033 females) (Table [1](#T1){ref-type="table"}). The three most common immune-mediated diseases were rheumatoid arthritis (44,611 cases), ulcerative colitis (23,610), and Graves' disease (22,062). Totally 66,509 patients with ischemic stroke and 428,031 patients with hemorrhagic strokes from 1987--2008 were included (Table [2](#T2){ref-type="table"}), of whom 10,905 (9,437 ischemic and 1,468 hemorrhagic strokes) were subsequently admitted to hospital after a first hospitalization for IMD (Table [2](#T2){ref-type="table"}). The comorbidities (defined as main or second hospital diagnosis) adjusted for are presented in Table [2](#T2){ref-type="table"}.

###### 

Number of cases hospitalizations of IMD and related conditions, 1987-2008

                                    **Men**   **Women**   **All**                     
  --------------------------------- --------- ----------- --------- -------- -------- --------
  **Immune-mediated disease**       No        \%          No        \%       No       \%
  Addison disease                   862       1.05        1190      0.89     2052     0.95
  Amyotrophic lateral sclerosis     2376      2.89        2055      1.53     4431     2.05
  Ankylosing spondylitis            2416      2.94        1061      0.79     3477     1.61
  Autoimmune hemolytic anemia       312       0.38        391       0.29     703      0.33
  Behcet disease                    146       0.18        138       0.10     284      0.13
  Celiac disease                    2639      3.21        4249      3.17     6888     3.18
  Chorea minor                      10        0.01        25        0.02     35       0.02
  Crohn disease                     9522      11.58       10700     7.98     20222    9.35
  Diabetes mellitus type I          9068      11.02       7664      5.72     16732    7.74
  Discoid lupus erythematosus       54        0.07        200       0.15     254      0.12
  Grave disease                     3764      4.58        18298     13.65    22062    10.20
  Hashimoto thyroiditis             1440      1.75        5115      3.82     6555     3.03
  Immune thrombocytopenic purpura   1905      2.32        2039      1.52     3944     1.82
  Localized scleroderma             90        0.11        422       0.31     512      0.24
  Lupoid hepatitis                  115       0.14        274       0.20     389      0.18
  Multiple sclerosis                3492      4.25        6892      5.14     10384    4.80
  Myasthenia gravis                 935       1.14        1149      0.86     2084     0.96
  Pernicious anemia                 1663      2.02        1868      1.39     3531     1.63
  Polyarteritis nodosa              437       0.53        386       0.29     823      0.38
  Polymyalgia rheumatica            5313      6.46        11183     8.34     16496    7.63
  Polymyositis/dermatomyositis      404       0.49        667       0.50     1071     0.50
  Primary biliary cirrhosis         124       0.15        675       0.50     799      0.37
  Psoriasis                         4471      5.44        4558      3.40     9029     4.17
  Reiter disease                    280       0.34        58        0.04     338      0.16
  Rheumatic fever                   236       0.29        228       0.17     464      0.21
  Rheumatoid arthritis              12080     14.69       32531     24.27    44611    20.63
  Sarcoidosis                       2847      3.46        2518      1.88     5365     2.48
  Sjören syndrome                   125       0.15        1175      0.88     1300     0.60
  Systemic lupus erythematosus      742       0.90        3437      2.56     4179     1.93
  Systemic sclerosis                402       0.49        1356      1.01     1758     0.81
  Ulcerative colitis                12963     15.76       10647     7.94     23610    10.92
  Wegener granulomatosis            1025      1.25        884       0.66     1909     0.88
  All                               82258     100.00      134033    100.00   216291   100.00

###### 

Number of cases of stroke, 1987-2008

                                                           **All stroke events**   **Subsequent stroke events of auto immune disorders patients**                                                                 
  -------------------------------------------------------- ----------------------- ---------------------------------------------------------------- -------------------- ------------------ ------ ------- ------ -------
                                                           Hemorrhagic stroke      Ischeamic stroke                                                 Hemorrhagic stroke   Ischeamic stroke                         
  Characteristics                                          No.                     \%                                                               No.                  \%                 No.    \%      No.    \%
  Gender                                                                                                                                                                                                           
  Men                                                      36639                   55.1                                                             216802               50.7               566    38.6    3216   34.1
  Women                                                    29870                   44.9                                                             211229               49.3               902    61.4    6221   65.9
  Age at diagnosis (yrs)                                                                                                                                                                                           
  \<50                                                     5070                    7.6                                                              13632                3.2                73     5.0     221    2.3
  50-59                                                    6857                    10.3                                                             29285                6.8                120    8.2     439    4.7
  60-69                                                    12399                   18.6                                                             71089                16.6               249    17.0    1263   13.4
  70-79                                                    21079                   31.7                                                             145288               33.9               476    32.4    3208   34.0
  \> = 80                                                  21104                   31.7                                                             168737               39.4               550    37.5    4306   45.6
  Period of diagnosis (yrs)                                                                                                                                                                                        
  1987-91                                                  13074                   19.7                                                             90088                21.0               134    9.1     832    8.8
  1992-96                                                  15114                   22.7                                                             110525               25.8               299    20.4    2183   23.1
  1997-01                                                  15773                   23.7                                                             97993                22.9               389    26.5    2626   27.8
  2002-08                                                  22548                   33.9                                                             129425               30.2               646    44.0    3796   40.2
  Socioeconomic status                                                                                                                                                                                             
  Farmers                                                  4797                    7.2                                                              34375                8.0                109    7.4     773    8.2
  Self-employed                                            4911                    7.4                                                              31497                7.4                95     6.5     654    6.9
  Professionals                                            4726                    7.1                                                              25561                6.0                70     4.8     438    4.6
  White collar workers                                     18912                   28.4                                                             119320               27.9               476    32.4    2773   29.4
  Workers                                                  29487                   44.3                                                             197833               46.2               653    44.5    4406   46.7
  Others                                                   3676                    5.5                                                              19445                4.5                65     4.4     393    4.2
  Region of residence                                                                                                                                                                                              
  Big cities                                               22409                   33.7                                                             145119               33.9               429    29.2    2915   30.9
  Northern Sweden                                          12936                   19.4                                                             80680                18.8               310    21.1    1972   20.9
  Southern Sweden                                          31164                   46.9                                                             202232               47.2               729    49.7    4550   48.2
  Hospitalization for obesity                                                                                                                                                                                      
  Yes                                                      114                     0.2                                                              703                  0.2                2      0.1     30     0.3
  No                                                       66395                   99.8                                                             427328               99.8               1466   99.9    9407   99.7
  Hospitalization for alcoholism                                                                                                                                                                                   
  Yes                                                      2265                    3.4                                                              7448                 1.7                45     3.1     143    1.5
  No                                                       64244                   96.6                                                             420583               98.3               1423   96.9    9294   98.5
  Hospitalization for chronic lower respiratory diseases                                                                                                                                                           
  Yes                                                      2067                    3.1                                                              18287                4.3                63     4.3     613    6.5
  No                                                       64442                   96.9                                                             409744               95.7               1405   95.7    8824   93.5
  Hospitalization for hypertension                                                                                                                                                                                 
  Yes                                                      2254                    3.4                                                              16998                4.0                48     3.3     434    4.6
  No                                                       64255                   96.6                                                             411033               96.0               1420   96.7    9003   95.4
  Hospitalization for diabetes type II                                                                                                                                                                             
  Yes                                                      2425                    3.6                                                              28091                6.6                77     5.2     726    7.7
  No                                                       64084                   96.4                                                             399940               93.4               1391   94.8    8711   92.3
  Hospitalization for artrial fibrillation                                                                                                                                                                         
  Yes                                                      4174                    6.3                                                              47257                11.0               134    9.1     1351   14.3
  No                                                       62335                   93.7                                                             380774               89.0               1334   90.9    8086   85.7
  Hospitalization for heart failure                                                                                                                                                                                
  Yes                                                      4619                    6.9                                                              63904                14.9               129    8.8     1749   18.5
  No                                                       61890                   93.1                                                             364127               85.1               1339   91.2    7688   81.5
  Hospitalization for renal disease                                                                                                                                                                                
  Yes                                                      2656                    4.0                                                              19793                4.6                105    7.2     718    7.6
  No                                                       63853                   96.0                                                             408238               95.4               1363   92.8    8719   92.4
  Hospitalization for sepsis                                                                                                                                                                                       
  Yes                                                      2167                    3.3                                                              15738                3.7                77     5.2     615    6.5
  No                                                       64342                   96.7                                                             412293               96.3               1391   94.8    8822   93.5
  Hospitalization for coronary heart disease                                                                                                                                                                       
  Yes                                                      9323                    14.0                                                             108895               25.4               234    15.9    2589   27.4
  No                                                       57186                   86.0                                                             319136               74.6               1234   84.1    6848   72.6
  All                                                      66509                   100.0                                                            428031               100.0              1468   100.0   9437   100.0

Hemorrhagic stroke
------------------

A total of 66,509 individuals were hospitalized with a main diagnosis of hemorrhagic stroke (Table [2](#T2){ref-type="table"}), of whom 1,468 (2·2% of hemorrhagic strokes) had been admitted to hospital due to an IMD (Table [2](#T2){ref-type="table"}). The risk of hemorrhagic stroke was significantly increased during the whole follow-up period for 15 of the 32 IMDs studied (Table [3](#T3){ref-type="table"}). The overall risk of hemorrhagic stroke during the first year after hospitalization for an IMD was 2·65 (95% CI 2·27--3·08). The overall risk of hemorrhagic stroke decreased over time, to 1·83 after 1--5 years (95% CI 1·69--1·98), 1·63 after 5--10 years (95% CI 1·47--1·80) and 1·47 after 10+ years (95% CI 1·31--1·65).

###### 

SIR for subsequent hemorrhagic stroke of patients with IMD

                                    **Follow-up interval (years)**                                                                                                                                                                                          
  --------------------------------- -------------------------------- ---------- ---------- ----------- ----- ---------- ---------- ---------- -------- ---------- ---------- ---------- ----- ---------- ---------- ---------- ------ ---------- ---------- ----------
                                    \<1                              1-5        5-10       \> = 10     All                                                                                                                                                  
  Immune-mediated diseases          O                                SIR        95% CI     O           SIR   95% CI     O          SIR        95% CI   O          SIR        95% CI     O     SIR        95% CI                                             
  Addison´s disease                 2                                2.70       0.25       9.94        2     0.64       0.06       2.34       1        0.42       0.00       2.41       1     0.55       0.00       3.17       6      0.74       0.27       1.63
  Amyotrophic lateral sclerosis     1                                0.47       0.00       2.68        2     1.30       0.12       4.78       1        1.82       0.00       10.42      0                                      4      0.89       0.23       2.30
  Ankylosing spondylitis            6                                **8.11**   **2.92**   **17.76**   15    **3.43**   **1.92**   **5.68**   7        1.66       0.66       3.44       14    **2.28**   **1.24**   **3.84**   42     **2.72**   **1.96**   **3.67**
  Autoimmune hemolytic anemia       1                                3.13       0.00       17.91       4     2.96       0.77       7.66       1        1.15       0.00       6.59       2     2.99       0.28       10.98      8      **2.49**   **1.06**   **4.93**
  Behcet´s disease                  1                                33.33      0.01       191.08      0                                      0                                         0                                      1      1.67       0.00       9.55
  Celiac disease                    2                                3.57       0.34       13.13       6     2.08       0.75       4.56       7        **2.69**   **1.07**   **5.58**   8     **2.65**   **1.13**   **5.25**   23     **2.54**   **1.61**   **3.81**
  Chorea minor                      0                                                                  0                                      0                                         0                                      0                             
  Crohn disease                     5                                1.47       0.46       3.46        47    **2.60**   **1.91**   **3.46**   19       1.19       0.72       1.87       24    **1.57**   **1.00**   **2.34**   95     **1.80**   **1.46**   **2.21**
  Diabetes mellitus type I          0                                                                  2     2.50       0.24       9.19       1        1.11       0.00       6.37       2     1.01       0.09       3.70       5      1.32       0.42       3.10
  Discoid lupus erythematosus       1                                11.11      0.00       63.69       1     2.33       0.00       13.33      0                                         0                                      2      1.87       0.18       6.87
  Grave´s disease                   8                                1.53       0.65       3.02        58    **1.77**   **1.35**   **2.29**   48       **1.61**   **1.18**   **2.13**   41    **1.48**   **1.06**   **2.02**   155    **1.62**   **1.38**   **1.90**
  Hashimoto´s thyroiditis           4                                1.47       0.38       3.79        27    **2.01**   **1.32**   **2.93**   19       **2.10**   **1.26**   **3.29**   11    1.37       0.68       2.46       61     **1.84**   **1.40**   **2.36**
  Immune thrombocytopenic purpura   8                                **8.60**   **3.67**   **17.03**   12    **2.81**   **1.45**   **4.92**   6        2.18       0.79       4.78       2     1.23       0.12       4.54       28     **2.93**   **1.94**   **4.23**
  Localized scleroderma             0                                                                  1     0.93       0.00       5.36       1        0.85       0.00       4.90       6     **4.32**   **1.55**   **9.46**   8      2.11       0.90       4.17
  Lupoid hepatitis                  0                                                                  0                                      0                                         0                                      0                             
  Multiple sclerosis                4                                1.82       0.47       4.70        15    1.36       0.76       2.25       9        1.09       0.49       2.08       6     0.94       0.34       2.06       34     1.22       0.84       1.71
  Myasthenia gravis                 1                                1.22       0.00       6.99        8     2.09       0.89       4.14       6        2.17       0.78       4.76       0                                      15     1.62       0.90       2.68
  Pernicious anemia                 4                                2.15       0.56       5.56        18    1.67       0.99       2.65       13       1.52       0.81       2.61       7     0.99       0.39       2.06       42     **1.49**   **1.07**   **2.01**
  Polyarteritis nodosa              2                                5.41       0.51       19.88       0     0.00       0.54       2.19       3        1.91       0.36       5.66       0                                      5      1.00       0.31       2.34
  Polymyalgia rheumatica            21                               **2.06**   **1.28**   **3.16**    78    **1.42**   **1.12**   **1.77**   65       **1.67**   **1.29**   **2.13**   40    **1.49**   **1.06**   **2.03**   204    **1.56**   **1.35**   **1.79**
  Polymyositis/ dermatomyositis     1                                2.63       0.00       15.08       3     1.95       0.37       5.77       1        1.18       0.00       6.74       1     2.08       0.00       11.94      6      1.85       0.66       4.04
  Primary biliary cirrhosis         1                                2.08       0.00       11.94       3     1.76       0.33       5.22       2        2.17       0.20       7.99       0                                      6      1.87       0.67       4.10
  Psoriasis                         9                                **2.88**   **1.31**   **5.50**    32    **1.83**   **1.25**   **2.59**   23       1.51       0.95       2.26       21    1.32       0.81       2.02       85     **1.64**   **1.31**   **2.03**
  Reiter´s disease                  0                                                                  1     2.94       0.00       16.86      1        2.56       0.00       14.70      0                                      2      1.42       0.13       5.22
  Rheumatic fever                   1                                7.69       0.00       44.09       0                                      0                                         1     1.72       0.00       9.88       2      1.04       0.10       3.81
  Rheumatoid arthritis              65                               **3.27**   **2.52**   **4.17**    191   **2.03**   **1.76**   **2.34**   109      **1.92**   **1.57**   **2.31**   61    **1.78**   **1.36**   **2.29**   426    **2.08**   **1.89**   **2.29**
  Sarcoidosis                       3                                2.48       0.47       7.34        12    1.87       0.96       3.28       14       **2.26**   **1.23**   **3.80**   6     0.79       0.28       1.73       35     **1.64**   **1.14**   **2.28**
  Sjögren´s syndrome                0                                                                  3     1.35       0.25       4.00       2        1.03       0.10       3.77       0                                      5      0.81       0.26       1.90
  Systemic lupus erythematosus      9                                **8.65**   **3.92**   **16.50**   13    **2.89**   **1.53**   **4.95**   4        1.17       0.31       3.03       6     1.91       0.69       4.19       32     **2.65**   **1.81**   **3.74**
  Systemic sclerosis                2                                3.17       0.30       11.67       5     2.67       0.84       6.29       3        2.73       0.51       8.07       2     3.45       0.33       12.68      12     **2.87**   **1.48**   **5.03**
  Ulcerative colitis                7                                1.45       0.57       3.00        40    **1.45**   **1.03**   **1.97**   28       1.21       0.80       1.74       33    1.44       0.99       2.02       108    **1.37**   **1.13**   **1.66**
  Wegener´s granulomatosis          6                                **5.83**   **2.10**   **12.76**   3     0.90       0.17       2.67       2        1.08       0.10       3.95       0                                      11     1.47       0.73       2.63
  All                               175                              **2.65**   **2.27**   **3.08**    602   **1.83**   **1.69**   **1.98**   396      **1.63**   **1.47**   **1.80**   295   **1.47**   **1.31**   **1.65**   1468   **1.75**   **1.66**   **1.84**

O = observed number of cases; SIR = standardized incidence ratio; CI = confidence interval.

Bold type: 95% CI does not include 1.00.

Adjusted for age, period, socioeconomic status, region of residence, hospitalization of chronic lower respiratory diseases, obesity, alcoholism, hypertension, diabetes, atrial fibrillation, heart failure, renal disease, sepsis, and coronary heart disease.

The risk of hemorrhagic stroke was ≥2 during the first year after hospitalization for seven IMD (Table [3](#T3){ref-type="table"}): ankylosing spondylitis, immune thrombocytopenic purpura, polymyalgia rheumatica, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, and Wegener´s granulomatosis. For seven IMDs, the risk of hemorrhagic stroke was increased 10+ years after hospitalization (Table [3](#T3){ref-type="table"}): ankylosing spondylitis, celiac disease, Crohn´s disease, Graves' disease, localized scleroderma, polymyalgia rheumatica, and rheumatoid arthritis.

Hemorrhagic stroke and age and sex
----------------------------------

The overall risk of hemorrhagic stroke was increased for both sexes at all different follow-up periods (Additional file [1](#S1){ref-type="supplementary-material"} Tables S2 and S3). The overall risk of hemorrhagic stroke was increased in all age groups for both males and females (\<50, 50--59, 60--69, 70--79, and 80+ years) (Additional file [1](#S1){ref-type="supplementary-material"} Tables S4, S5 and S6).

Ischemic stroke
---------------

A total of 428,031 individuals were hospitalized with a main diagnosis of ischemic stroke (Table [2](#T2){ref-type="table"}), of whom 9,437 (2·2% of all ischemic stroke cases) had been admitted to hospital due to an IMD (Table [2](#T2){ref-type="table"}). The variables for which the SIRs were adjusted are presented in Table [1](#T1){ref-type="table"}. The risk of ischemic stroke was increased during the whole follow-up period for 20 of the 32 IMDs studied (Table [4](#T4){ref-type="table"}). The overall risk of ischemic stroke during the first year after hospitalization for an IMD was 2·02 (95% CI 1·90--2·14). The overall risk of ischemic stroke decreased over time, to1·50 after 1--5 years (95% CI 1·46--1·55), 1·38 after 5--10 years (95% CI 1·33--1·43) and 1·29 after 10+ years (95% CI 1·23--1·35) (Table [4](#T4){ref-type="table"}).

Ischemic stroke

###### 

SIR for subsequent ischemic stroke of patients with IMD

                                    **Follow-up interval (years)**                                                                                                                                                                                           
  --------------------------------- -------------------------------- ---------- ---------- ---------- ------ ---------- ---------- ---------- -------- ---------- ---------- ---------- ------ ---------- ---------- ---------- ------ ---------- ---------- ----------
                                    \<1                              1-5        5-10       \> = 10    All                                                                                                                                                    
  Immune-mediated diseases          O                                SIR        95% CI     O          SIR    95% CI     O          SIR        95% CI   O          SIR        95% CI     O      SIR        95% CI                                             
  Addison´s disease                 14                               **2.71**   **1.48**   **4.56**   28     1.17       0.78       1.69       30       **1.90**   **1.28**   **2.72**   11     0.97       0.48       1.74       83     **1.48**   **1.18**   **1.83**
  Amyotrophic lateral sclerosis     7                                0.53       0.21       1.10       16     1.52       0.87       2.47       7        1.77       0.70       3.67       2      1.15       0.11       4.23       32     1.09       0.74       1.54
  Ankylosing spondylitis            8                                1.62       0.69       3.21       44     **1.55**   **1.13**   **2.08**   24       0.98       0.63       1.46       35     1.08       0.75       1.50       111    **1.23**   **1.01**   **1.48**
  Autoimmune hemolytic anemia       4                                1.45       0.38       3.75       12     1.00       0.51       1.75       19       **2.51**   **1.51**   **3.93**   5      1.23       0.39       2.90       40     **1.51**   **1.08**   **2.06**
  Behcet´s disease                  1                                4.00       0.00       22.93      1      0.65       0.00       3.70       0                                         1      1.43       0.00       8.19       3      0.78       0.15       2.29
  Celiac disease                    9                                2.17       0.99       4.14       29     1.28       0.86       1.84       21       1.17       0.72       1.78       26     1.47       0.96       2.15       85     **1.36**   **1.09**   **1.68**
  Chorea minor                      0                                                                 1      2.27       0.00       13.03      0                                         0                                       1      1.11       0.00       6.37
  Crohn disease                     49                               **2.15**   **1.59**   **2.84**   160    **1.33**   **1.13**   **1.55**   103      1.11       0.91       1.35       97     1.15       0.93       1.40       409    **1.28**   **1.16**   **1.41**
  Diabetes mellitus type I          1                                6.25       0.00       35.83      2      0.45       0.04       1.65       5        2.75       0.87       6.46       17     **5.00**   **2.91**   **8.02**   25     **2.54**   **1.64**   **3.76**
  Discoid lupus erythematosus       3                                4.23       0.80       12.51      3      0.99       0.19       2.92       1        0.47       0.00       2.70       3      1.55       0.29       4.60       10     1.28       0.61       2.37
  Grave´s disease                   101                              **2.15**   **1.76**   **2.62**   402    **1.39**   **1.26**   **1.53**   348      **1.36**   **1.22**   **1.51**   276    **1.27**   **1.12**   **1.43**   1127   **1.39**   **1.31**   **1.48**
  Hashimoto´s thyroiditis           77                               **2.99**   **2.36**   **3.74**   211    **1.73**   **1.50**   **1.98**   115      **1.39**   **1.14**   **1.67**   82     **1.28**   **1.02**   **1.59**   485    **1.64**   **1.50**   **1.80**
  Immune thrombocytopenic purpura   16                               **2.35**   **1.34**   **3.83**   55     **1.77**   **1.33**   **2.30**   19       0.94       0.57       1.48       14     1.20       0.65       2.01       104    **1.49**   **1.22**   **1.81**
  Localized scleroderma             2                                1.28       0.12       4.71       13     1.25       0.66       2.14       18       **1.72**   **1.01**   **2.72**   11     1.04       0.51       1.86       44     1.33       0.97       1.79
  Lupoid hepatitis                  3                                4.48       0.84       13.25      4      1.98       0.52       5.12       0                                         0                                       7      2.10       0.83       4.36
  Multiple sclerosis                40                               **3.05**   **2.18**   **4.15**   73     1.09       0.85       1.37       55       1.11       0.83       1.44       35     0.95       0.66       1.32       203    **1.22**   **1.06**   **1.40**
  Myasthenia gravis                 6                                1.01       0.36       2.21       38     1.36       0.96       1.87       23       1.20       0.76       1.80       13     1.08       0.57       1.85       80     1.23       0.97       1.53
  Pernicious anemia                 25                               **1.56**   **1.01**   **2.31**   138    **1.49**   **1.25**   **1.76**   89       1.23       0.99       1.52       74     **1.44**   **1.13**   **1.80**   326    **1.40**   **1.25**   **1.56**
  Polyarteritis nodosa              5                                1.23       0.39       2.89       20     1.30       0.79       2.02       11       1.05       0.52       1.88       10     1.13       0.54       2.08       46     1.19       0.87       1.58
  Polymyalgia rheumatica            165                              **1.76**   **1.50**   **2.05**   761    **1.50**   **1.39**   **1.61**   529      **1.54**   **1.41**   **1.68**   322    **1.53**   **1.37**   **1.71**   1777   **1.54**   **1.47**   **1.61**
  Polymyositis/ dermatomyositis     10                               **3.46**   **1.65**   **6.39**   13     1.19       0.63       2.03       6        1.07       0.38       2.34       5      1.73       0.55       4.07       34     **1.52**   **1.05**   **2.13**
  Primary biliary cirrhosis         4                                1.54       0.40       3.98       11     1.45       0.72       2.60       4        0.91       0.24       2.35       1      2.17       0.00       12.46      20     1.33       0.81       2.05
  Psoriasis                         44                               **1.92**   **1.39**   **2.58**   217    **1.65**   **1.44**   **1.89**   163      **1.53**   **1.30**   **1.78**   144    **1.41**   **1.19**   **1.66**   568    **1.56**   **1.44**   **1.70**
  Reiter´s disease                  0                                                                 5      2.02       0.64       4.76       6        2.47       0.89       5.41       2      0.56       0.05       2.07       13     1.47       0.78       2.52
  Rheumatic fever                   5                                **3.91**   **1.23**   **9.19**   10     1.66       0.79       3.06       14       **3.04**   **1.65**   **5.11**   7      1.81       0.72       3.75       36     **2.28**   **1.59**   **3.16**
  Rheumatoid arthritis              345                              **2.08**   **1.86**   **2.31**   1266   **1.66**   **1.57**   **1.75**   663      **1.45**   **1.34**   **1.56**   326    **1.30**   **1.16**   **1.45**   2600   **1.59**   **1.53**   **1.65**
  Sarcoidosis                       9                                0.97       0.44       1.85       70     **1.43**   **1.12**   **1.81**   51       1.12       0.83       1.47       56     1.08       0.81       1.40       186    **1.19**   **1.03**   **1.38**
  Sjögren´s syndrome                10                               **2.57**   **1.22**   **4.75**   28     1.38       0.92       1.99       15       0.96       0.54       1.59       15     1.26       0.70       2.08       68     **1.31**   **1.02**   **1.67**
  Systemic lupus erythematosus      19                               **2.21**   **1.33**   **3.46**   88     **2.33**   **1.87**   **2.87**   54       **1.92**   **1.44**   **2.51**   30     1.26       0.85       1.80       191    **1.94**   **1.68**   **2.24**
  Systemic sclerosis                11                               1.90       0.94       3.41       28     1.22       0.81       1.77       11       1.19       0.59       2.14       2      0.39       0.04       1.43       52     1.21       0.90       1.58
  Ulcerative colitis                71                               **2.15**   **1.68**   **2.71**   231    **1.27**   **1.11**   **1.45**   162      1.09       0.92       1.27       146    1.05       0.89       1.24       610    **1.21**   **1.12**   **1.31**
  Wegener´s granulomatosis          11                               1.66       0.82       2.98       12     0.47       0.24       0.83       26       **1.54**   **1.00**   **2.25**   12     1.69       0.87       2.96       61     1.09       0.83       1.40
  All                               1075                             **2.02**   **1.90**   **2.14**   3990   **1.50**   **1.46**   **1.55**   2592     **1.38**   **1.33**   **1.43**   1780   **1.29**   **1.23**   **1.35**   9437   **1.46**   **1.43**   **1.49**

O = observed number of cases; SIR = standardized incidence ratio; CI = confidence interval.

Bold type: 95% CI does not include 1.00.

Adjusted for age, period, socioeconomic status, region of residence, hospitalization of chronic lower respiratory diseases, obesity, alcoholism, hypertension, diabetes, atrial fibrillation, heart failure, renal disease, sepsis, and coronary heart disease.

The risk of ischemic stroke was ≥2 during the first year after hospitalization for twelve IMDs (Table [4](#T4){ref-type="table"}): Addison's disease, Crohn´s disease, Grave´s disease, Hashimoto´s thyroiditis, immune thrombocytopenic purpura, multiple sclerosis, polymyositis/dermatomyositis, rheumatic fever, rheumatoid arthritis, Sjögren's syndrome, systemic lupus erythematosus, and ulcerative colitis. For seven IMDs, the risk of ischemic stroke was increased 10+ years after hospitalization: diabetes mellitus type 1, Graves' disease, Hashimoto's thyroiditis, pernicious anemia, polymyalgia rheumatica, psoriasis, and rheumatoid arthritis (Table [4](#T4){ref-type="table"}).

Ischemic stroke and age and sex
-------------------------------

The overall risk of ischemic or hemorrhagic stroke was increased for both sexes at all different follow-up periods (Additional file [1](#S1){ref-type="supplementary-material"} Tables S7 and S8). The overall risk of ischemic stroke was increased in all age groups for both sexes (\<50, 50--59, 60--69, 70--79, and 80+ years) (Additional file [1](#S1){ref-type="supplementary-material"} Tables S9, S10 and S11).

Time period and hemorrhagic and ischemic stroke
-----------------------------------------------

The overall risk for both hemorrhagic and ischemic stroke was slightly higher between 1987 and 1996 (1.98 95% CI 1.78-2.20 and 1.51 95% CI 1.45-1.57, respectively) than between 1997 and 2008 (1.58 95% CI 1.48-1.69 and 1.38 95% CI 1.34-1.41, respectively) (Additional file [1](#S1){ref-type="supplementary-material"} Tables S12 and S13).

Discussion
==========

The present study is the first nationwide study of IMDs and ischemic and hemorrhagic stroke. The results indicate that several IMDs increase the risk of hospitalization for both ischemic and/or hemorrhagic stroke. The relative risk of ischemic and hemorrhagic stroke during the first year after hospitalization with certain IMDs was even higher than the risks associated with many traditional risk factors for ischemic and hemorrhagic stroke \[[@B1],[@B25]\]. Although it declined over time, the overall risk of ischemic and hemorrhagic stroke remained elevated for 10 or more years for some IMDs. The results of our study are in line with previous studies linking rheumatoid arthritis \[[@B3],[@B5],[@B6],[@B8]-[@B12],[@B20]\], systemic lupus erythematosus \[[@B3],[@B5],[@B6],[@B8],[@B13]-[@B15],[@B19]\], Sjögren´s disease \[[@B3],[@B5],[@B6],[@B16]\], systemic vasculitis \[[@B3],[@B5]\], inflammatory bowel disease \[[@B3],[@B5],[@B8],[@B17]\], and psoriasis \[[@B8],[@B18]\] to an increased risk of cardiovascular disease. However, what distinguishes our study from these other studies is its comparison of large numbers of patients and 32 types of IMDs with the general population in a nationwide setting, as well as the long-term follow-up of patients and the determination of risk for both ischemic and hemorrhagic stroke. Moreover, we also found a number of novel associations between IMDs and ischemic and hemorrhagic stroke. The results of the present study suggest that increased risk of subsequent ischemic and hemorrhagic stroke is a common feature of several IMDs, not just selected conditions such as systemic lupus erythematosus \[[@B19]\] and rheumatoid arthritis \[[@B20]\].

Although the increased risk of ischemic and hemorrhagic stroke may have different underlying causes in different IMDs, a general link between systemic inflammation and atherothrombosis has been indicated \[[@B2]-[@B8]\]. In some conditions, such as in immune thrombocytopenic purpura, hemorrhagic stroke may occur as the direct result of thrombocytopenia. The formation of autoantibodies may, in special cases, also contribute to stroke \[[@B26]\]. The increased risk of stroke may be specific for more severe cases of IMDs, since the patients in our study had been admitted to hospital. The effects of treatment---corticosteroids promote hemostasis \[[@B27]\]---and the effect of inflammation on coagulation \[[@B7]\] may also contribute to the identified associations. Hypothetically, the fact that the risk of ischemic and hemorrhagic stroke decreased over time may suggest that it is linked to the inflammatory activity of the IMDs, which is likely to decrease over time due to treatment. In line with this hypothesis, in several studies disease activity appears to be linked with atherosclerosis progression \[[@B2]-[@B8],[@B28],[@B29]\]. However, as we lack treatment data, we cannot prove this hypothesis but in this context it is interesting that the relative risk of both hemorrhagic and ischemic stroke was lower between 1997 and 2008 than between 1987 and 1996 (Additional file [1](#S1){ref-type="supplementary-material"} Tables S12 and S13).

The present study has certain limitations. For example, we had no data on general cardiovascular disease risk factors such as weight, smoking, and diet. It is unrealistic to gather such data for an entire national population. However, we did adjust for socioeconomic status, which is associated with risk factors such as smoking. Aspirin and non-steroidal anti-inflammatory drugs (NSAID) may affect the risk of ischemic and hemorrhagic stroke \[[@B30],[@B31]\]. However, we had no access to treatment data. Adjustment was, however, made for several comorbidities (chronic lower respiratory diseases, obesity, alcoholism and alcohol-related liver disease, type 2 diabetes mellitus, hypertension, atrial fibrillation, coronary heart diseases, heart failure, renal disease and sepsis). Still, residual bias may remain due to hospitalization of the most severe cases with IMD. However, all cases with previous or coexisting stroke were excluded to avoid selection bias. Totally, 8113 IMD patients with previous or coexisting ischemic stroke and 1416 with hemorrhagic stroke were excluded from the study, which in turn instead may underestimate the stroke risk. In fact, our results are within the limit for published cardiovascular disease risk in IMDs like RA \[[@B3],[@B5],[@B6],[@B8]-[@B12],[@B20]\] and SLE \[[@B3],[@B5],[@B6],[@B8],[@B13]-[@B15],[@B19]\]. Thus, the estimated risks of stroke in IMD patients appear to be fairly valid. Anyway, the present study reflects the real world risks for stroke among hospitalized IMD (without previous stroke or at the same time as first hospitalization for IMD). All cases of ischemic and hemorrhagic stroke in Sweden should, according to official guidelines, be treated at hospitals \[[@B32]\]. Moreover, hospitalization incidence rates were calculated for the whole follow-up period, divided into five time periods, and adjustments were made for possible changes in hospitalization rates over time.

This study also has a number of strengths. The study reflects the situation in real world medicine during 22 years in a country with a high standard in the medical diagnosis \[[@B22],[@B23],[@B33]-[@B35]\]. The study population included all individuals clinically diagnosed with IMD and ischemic and hemorrhagic stroke in hospital during the study period, which eliminated recall bias. Because of the personal identification number assigned to each resident in Sweden, it was possible to trace all subjects for the whole follow-up period. Data on occupation were 99·2% complete (1980 and 1990 censuses), which enabled us to adjust our models for socioeconomic status. A further strength of the present study was the use of validated hospital discharge data. The Hospital Discharge Register has high validity \[[@B22],[@B23],[@B33]-[@B35]\], especially for cardiovascular disorders such as stroke, for which approximately 95% of diagnoses have been shown to be correct \[[@B33]-[@B35]\]. Though, the positive predictive value (PPV) may differ between diagnoses in the Swedish Hospital Discharge Register, the PPV is generally around 85-95% \[[@B35]\].

Conclusions
===========

In summary, the risk of hospitalization for ischemic and hemorrhagic stroke was, for several immune-mediated diseases studied, found to be significantly associated. The risk of ischemic and hemorrhagic stroke during the first year after hospitalization with an immune-mediated disease was high for certain IMDs. Although it decreased over time, for some IMDs the risk of ischemic and hemorrhagic stroke remained elevated for more than 10 years. The findings of the present study suggest that many IMDs are linked to cerebrovascular disease. Future studies could elucidate the mechanisms behind stroke in specific IMDs.
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